Literature DB >> 19429825

Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury.

Nauman Ahmad1, Yigang Wang, Ailia K Ali, Muhammad Ashraf.   

Abstract

The ability of pharmacological preconditioning mimetics to confer long-lasting and sustained cardioprotection may be a logical criterion to develop a drug that can be used clinically for cardioprotection. We propose here that the use of long-acting phosphodiesterase-5 inhibitor, tadalafil, may confer sustained cardioprotection against ischemia. Tadalafil (5 mg/kg) was administered orally to male C57B/6J mice (n = 6 in each treatment subgroup at each time point studied). Hearts were isolated and subjected to 40 min of ischemia and 30 min of reperfusion on Langendorff's apparatus at 1, 12, 24, 36, 48, 60, 72, and 108 h after tadalafil administration. In 1- to 48-h subgroups, tadalafil was given once at 0 h only. In 60- and 72-h subgroups, tadalafil was given twice at 0 and 36 h. Similarly, in the 108-h subgroup, tadalafil was administered at 0, 36, and 72 h. In the same subgroups, wortmannin (15 microg/kg ip), an inhibitor of phosphatidylinositol 3-kinase or 5-hydroxydecanoic acid (5 mg/kg ip), an inhibitor of mitochondrial ATP-sensitive K(+) channels, was given together with tadalafil, and the hearts were subjected to ischemia-reperfusion at 36 h to determine whether the effect of tadalafil on ischemia-reperfusion injury was abolished. As a result, tadalafil treatment reduced left ventricular end-diastolic pressure and increased left ventricular developed pressure as well as reduced lactate dehydrogenase release. This protection remained till 36-40 h, and thereafter it vanished. The readministration of tadalafil at 36 and 72 h restored the protection till 108 h. Tadalafil treatment accelerated Akt phosphorylation in cardiac tissue and decreased myocyte apoptosis. The administration of wortmannin abolished the beneficial effects of tadalafil on hemodynamic parameters and myocyte apoptosis, together with significantly reduced Akt phosphorylation. 5-Hydroxydecanoic acid also abolished the antiapoptotic effect of tadalafil. It is concluded that tadalafil treatment induces the long-term protection of ischemic myocardium via phosphatidylinositol 3-kinase/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429825      PMCID: PMC2711726          DOI: 10.1152/ajpheart.00169.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  25 in total

1.  Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo.

Authors:  T Matsui; J Tao; F del Monte; K H Lee; L Li; M Picard; T L Force; T F Franke; R J Hajjar; A Rosenzweig
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

2.  Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.

Authors:  H Senzaki; C J Smith; G J Juang; T Isoda; S P Mayer; A Ohler; N Paolocci; G F Tomaselli; J M Hare; D A Kass
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

3.  Reperfusion induces myocardial apoptotic cell death.

Authors:  Z Q Zhao; M Nakamura; N P Wang; J N Wilcox; S Shearer; R S Ronson; R A Guyton; J Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2000-02       Impact factor: 10.787

4.  Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts.

Authors:  Eric R Gross; Anna K Hsu; Garrett J Gross
Journal:  Circ Res       Date:  2004-02-19       Impact factor: 17.367

Review 5.  Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

Authors:  Rakesh C Kukreja; Ramzi Ockaili; Fadi Salloum; Chang Yin; John Hawkins; Anindita Das; Lei Xi
Journal:  J Mol Cell Cardiol       Date:  2004-02       Impact factor: 5.000

6.  Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype.

Authors:  Jason N Peart; Garrett J Gross
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

7.  Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.

Authors:  Ramzi Ockaili; Fadi Salloum; John Hawkins; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09       Impact factor: 4.733

8.  Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.

Authors:  Fadi Salloum; Chang Yin; Lei Xi; Rakesh C Kukreja
Journal:  Circ Res       Date:  2003-03-13       Impact factor: 17.367

9.  Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits.

Authors:  Anindita Das; Ramzi Ockaili; Fadi Salloum; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04       Impact factor: 4.733

Review 10.  Phosphodiesterase type 5: expanding roles in cardiovascular regulation.

Authors:  David A Kass; Hunter C Champion; Joseph A Beavo
Journal:  Circ Res       Date:  2007-11-26       Impact factor: 17.367

View more
  10 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

2.  Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.

Authors:  Longhu Li; Husnain Kh Haider; Linlin Wang; Gang Lu; Muhammad Ashraf
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

Review 3.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

Review 4.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

5.  Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das; Saisudha Koka; Ramzi A Ockaili; Lei Xi
Journal:  Exp Clin Cardiol       Date:  2011

6.  Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.

Authors:  Husnain Kh Haider; Yun-Jung Lee; Shujia Jiang; Rafeeq P H Ahmed; Mok Ryon; Muhammad Ashraf
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

7.  A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanism.

Authors:  Shailaja Kesaraju Allani; Ramanjaneyulu Rayala; Oscar Rivera; Howard M Prentice; Xi Chen; Veronica Ramírez-Alcántara; Joshua Canzoneri; Janet Menzie-Suderam; Xupei Huang; Constantin Georgescu; Jonathan D Wren; Gary A Piazza; Herbert Weissbach
Journal:  J Pharmacol Exp Ther       Date:  2022-06-09       Impact factor: 4.402

Review 8.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

9.  Tadalafil, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair.

Authors:  Ibrahim Elmadbouh; Muhammad Ashraf
Journal:  Physiol Rep       Date:  2017-11

10.  Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.

Authors:  Simon G Anderson; David C Hutchings; Mark Woodward; Kazem Rahimi; Martin K Rutter; Mike Kirby; Geoff Hackett; Andrew W Trafford; Adrian H Heald
Journal:  Heart       Date:  2016-07-26       Impact factor: 5.994

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.